Sodium-glucose transporter 2 (SGLT2) inhibitors decrease the risk of acute kidney injury and severe hypoglycemia for those with diabetes, heart failure, and chronic kidney disease (CKD) but increase the risk of diabetic ketoacidosis.
Sodium-glucose transporter 2 (SGLT2) inhibitors decrease the risk of acute kidney injury and severe hypoglycemia for patients of 3 chronic diseases but increase the risk of diabetic ketoacidosis and other complications, a new study found.
Previous studies have assessed the safety profile of SGLT2 inhibitors in type 2 diabetes (T2D). The meta-analysis published in Diabetes and Vascular Disease Research was the first to assess the safety of these drugs not only in T2D but chronic kidney disease and chronic heart failure, the authors said.
Results showed the treatment with SGLT2 inhibitors vs. placebo reduced the risk of acute kidney injury (risk ratio [RR] 0.75; 95% CI, 0.66-0.85) and severe hypoglycemia (RR, 0.86; 95% CI, 0.71-1.03).
However, SGLT2 inhibitors vs. placebo significantly increased the risks of diabetic ketoacidosis (RR, 2.57; 95% CI, 1.53-4.31; P for drug effect <.001); genital infection (RR, 3.75; 95% CI, 3.00-4.67; P <.001); and volume depletion (RR, 1.14; 95% CI, 1.05-1.24; P = .002).
There were also trends toward increased risk of fracture (RR, 1.07; 95% CI, 0.99-1.16; P = .081); amputation (RR, 1.21; 95% CI, 0.97-1.51; P = .085), and urinary tract infection (RR, 1.07; 95% CI, 0.99-1.15; P = .074).
The findings are meant to guide clinicians in monitoring for these adverse events when treating patients with SGLT2 inhibitors, the authors said. Results of previous studies on the safety of SGLT2 inhibitors, which focused solely on T2D, produced inconsistent results.
The meta-analysis evaluated 8 randomized clinical trials and assessed 4 SGLT2 inhibitors: dapagliflozin, empagliflozin, ertugliflozin (Steglatro), and canagliflozin. The authors indicated that the evaluation of the safety profiles was consistent across all 3 diseases studied.
The authors said the meta-analysis was strong because all the original studies were high quality. One weakness, however, was that the patients in the studies had considerably different baseline characteristics, including the comorbidities involved. They recommended further studies to minimize ascertainment bias.
Three of the studies used in the meta-analysis were recent: DAPA-CKD, EMPEROR-Reduced, and VERTIS CV.
Reference
Qiu M, Ding L-L, Zhang M, et al. Safety of four SGLT2 inhibitors in three chronic diseases: A meta-analysis of large randomized trials of SGLT2 inhibitors. Diab Vasc Dis Res. Published online April 22, 2021. doi:10.1177/14791641211011016
Research Shows Prior Authorization Denials Delay Critical Immunology Care
May 10th 2024Results featured at the Academy of Managed Care Pharmacy 2024 annual meeting revealed a pattern of prior authorization rejections that could delay necessary therapeutic treatments for various patient groups.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Patients With Advanced, Recurrent Melanoma May Experience Lasting AEs From ICM Therapy
May 9th 2024A cross-sectional, mixed-methods study found that adverse effects (AEs) can occur even after 1 year of treatment with immune checkpoint modulator (ICM) therapy in patients with melanoma.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Goal Achievement in T1D Management Boosts Self-Efficacy, Self-Care Among Emerging Adults
May 9th 2024Findings from the FAMS-T1D study demonstrate that structured goal-setting and achievement significantly enhance self-efficacy and self-care in emerging adults who have type 1 diabetes (T1D).
Read More
Medication Adherence Star Ratings Measures, Health Care Resource Utilization, and Cost
May 9th 2024For patients prescribed diabetes, hypertension, and hyperlipidemia medications, nonadherence to CMS Star Ratings quality measures of medication adherence was associated with increased health care resource utilization and costs.
Read More